Literature DB >> 28031572

Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans.

Sarah Crunkhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28031572     DOI： 10.1038/nrd.2016.271

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

Authors:  Matthew E Kennedy; Andrew W Stamford; Xia Chen; Kathleen Cox; Jared N Cumming; Marissa F Dockendorf; Michael Egan; Larry Ereshefsky; Robert A Hodgson; Lynn A Hyde; Stanford Jhee; Huub J Kleijn; Reshma Kuvelkar; Wei Li; Britta A Mattson; Hong Mei; John Palcza; Jack D Scott; Michael Tanen; Matthew D Troyer; Jack L Tseng; Julie A Stone; Eric M Parker; Mark S Forman
Journal:  Sci Transl Med       Date:  2016-11-02       Impact factor: 17.956
  1 in total
  5 in total

1.  miR-15b represses BACE1 expression in sporadic Alzheimer's disease.

Authors:  Guohua Gong; Fengmao An; Yu Wang; Ming Bian; Li-Jun Yu; Chengxi Wei
Journal:  Oncotarget       Date:  2017-09-21

2.  Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease.

Authors:  Liang Feng; Yu-Ting Liao; Jin-Cai He; Cheng-Long Xie; Si-Yan Chen; Hui-Hui Fan; Zhi-Peng Su; Zhen Wang
Journal:  BMC Neurol       Date:  2018-01-09       Impact factor: 2.474

3.  Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice.

Authors:  Hong-Ying Wang; Min Wu; Jun-Ling Diao; Ji-Bin Li; Yu-Xiang Sun; Xiao-Qiu Xiao
Journal:  Acta Pharmacol Sin       Date:  2019-06-18       Impact factor: 6.150

4.  Studies on APP metabolism related to age-associated mitochondrial dysfunction in APP/PS1 transgenic mice.

Authors:  Lizhi Chen; Shicheng Xu; Tong Wu; Yijia Shao; Li Luo; Lingqi Zhou; Shanshan Ou; Hai Tang; Wenhua Huang; Kaihua Guo; Jie Xu
Journal:  Aging (Albany NY)       Date:  2019-11-19       Impact factor: 5.682

5.  MiR-124 acts as a target for Alzheimer's disease by regulating BACE1.

Authors:  Fengmao An; Guohua Gong; Yu Wang; Ming Bian; Lijun Yu; Chengxi Wei
Journal:  Oncotarget       Date:  2017-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.